311 results Stibbe advises Punch International and Accentis Stibbe assisted Punch International and Accentis with the 245 million EUR purchase of Punch's real property and the subsequent public offer on all shares of Accentis with the focus on semi-industrial property. Stibbe advises KBC Securities Stibbe assisted KBC Securities as underwriters on the IPO of ThromboGenics on Euronext Brussels. Stibbe advises on the IPO of Ziggo Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products. Stibbe advises leading Belgian bank Stibbe assisted a leading Belgian bank with a number of highly complex and sensitive litigation cases about the sale of Collateralized Debt Obligations (CDOs) to corporate and private clients during the period 2005-2007. Stibbe advises on the contemplated IPO of Agendia Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products. Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency. Stibbe advises worldwide seeds leader Stibbe assisted a worldwide seeds leader in negotiations on cooperation deals with competitors. Stibbe advises ING Advising ING Groep on its EUR 7.5 billion rights offering. Stibbe advises pharmaceutical multinational Stibbe assisted a pharmaceutical multinational in complex litigations. Stibbe advises Aegon Advising Morgan Stanley, Deutsche Bank and JP Morgan in their role as underwriters of the Dutch aspects of the equity issue in an accelerated bookbuild offering by AEGON N.V. Stibbe advises Wavin Stibbe advises Brazilian shareholders of InBev Stibbe assisted the Brazilian shareholders of InBev with the financing of their participation in the capital increase to fund its EUR 32.7 billion acquisition of Anheuser-Busch to create Anheuser-Busch InBev, the world's largest brewery. Stibbe advises Distrigas Stibbe assisted Distrigas in the auction controlled EUR 4.8 billion sale of the majority stake of Suez to ENI, in the subsequent takeover bid by ENI on all Distrigas NV shares, and in the transfer by Publigas of its entire stake in Distrigas to ENI. Stibbe advises on the IPO of Tornier Stibbe advises Cellerix Stibbe assisted Cellerix with its merger with Euronext-Brussels-listed Tigenix. Stibbe advises international manufacturer of automated logistics Stibbe advised a prominent international manufacturer of automated logistics and handling systems on the structuring and incorporation of its Chinese sales company in Hong Kong and Shanghai. Pagination Previous page Page 15 Current page 16 Page 17 Page 18 Next page
Stibbe advises Punch International and Accentis Stibbe assisted Punch International and Accentis with the 245 million EUR purchase of Punch's real property and the subsequent public offer on all shares of Accentis with the focus on semi-industrial property.
Stibbe advises KBC Securities Stibbe assisted KBC Securities as underwriters on the IPO of ThromboGenics on Euronext Brussels.
Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products.
Stibbe advises leading Belgian bank Stibbe assisted a leading Belgian bank with a number of highly complex and sensitive litigation cases about the sale of Collateralized Debt Obligations (CDOs) to corporate and private clients during the period 2005-2007.
Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products.
Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency.
Stibbe advises worldwide seeds leader Stibbe assisted a worldwide seeds leader in negotiations on cooperation deals with competitors.
Stibbe advises pharmaceutical multinational Stibbe assisted a pharmaceutical multinational in complex litigations.
Stibbe advises Aegon Advising Morgan Stanley, Deutsche Bank and JP Morgan in their role as underwriters of the Dutch aspects of the equity issue in an accelerated bookbuild offering by AEGON N.V.
Stibbe advises Brazilian shareholders of InBev Stibbe assisted the Brazilian shareholders of InBev with the financing of their participation in the capital increase to fund its EUR 32.7 billion acquisition of Anheuser-Busch to create Anheuser-Busch InBev, the world's largest brewery.
Stibbe advises Distrigas Stibbe assisted Distrigas in the auction controlled EUR 4.8 billion sale of the majority stake of Suez to ENI, in the subsequent takeover bid by ENI on all Distrigas NV shares, and in the transfer by Publigas of its entire stake in Distrigas to ENI.
Stibbe advises Cellerix Stibbe assisted Cellerix with its merger with Euronext-Brussels-listed Tigenix.
Stibbe advises international manufacturer of automated logistics Stibbe advised a prominent international manufacturer of automated logistics and handling systems on the structuring and incorporation of its Chinese sales company in Hong Kong and Shanghai.